Pharmacy Focus Episode 26: Cannabis as a Treatment For PTSD
June 25th 2021The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.
Listen
Review Finds Minimal Evidence That Dietary Supplements Lead to Weight Loss
June 25th 2021The investigators conducted a systematic review of the existing literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to evaluate the efficacy of dietary supplements and alternative therapies for weight loss in participants aged 18 and older.
Read More
Updated Clinical Trial Results Demonstrate Durable Response to Loncastuximab Tesirine-lpyl
June 24th 2021Results from the LOTIS-2 and LOTIS-3 trials show durable responses and a manageable toxicity profile among patients with both diffuse large B-cell lymphoma and mantle cell lymphoma treated with loncastuximab tesirine-lpyl (Zynlonta).
Read More
Tip of the Week: Maximize Your Employees’ Contribution to Collaborate with Home Health Agencies
June 24th 2021Community pharmacy teams can help reduce hospitalizations through the provision of medication reconciliation, which adjudicates discrepancies such as therapeutic omissions, duplications, dosing errors, drug interactions, and unintentional therapeutic changes.
Read More
Study Reinforces Community Pharmacists Play a 'Key Clinical Role' in COVID-19 Vaccination Process
June 23rd 2021The research team discovered that community pharmacists, as a skilled clinical workforce, could positively contribute to the future of COVID-19 vaccination programs by continuing to be active in COVID-19 vaccination campaigns.
Read More
Bia Labate, PhD, public education and culture specialist at the Multidisciplinary Association for Psychedelic Studies, and Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discuss the psychedelic medicine market and the outlook for the field.
Watch
Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More